<a href="https://laohu8.com/S/CDIO">Cardio Diagnostics</a> Receives Preliminary Gapfill Payment Rates from CMS for AI-Driven Cardiovascular Tests, Expanding Medicare Access
Cardio Diagnostics Holdings Inc., an AI-powered precision cardiovascular medicine company, has announced a significant milestone in its regulatory journey with the Centers for Medicare and Medicaid Services $(CMS)$. The CMS, through the MolDX program, has issued preliminary gapfill payment rates for Cardio Diagnostics' AI-driven cardiovascular tests. The rates are set at $350 for the Epi+Gen CHD™ test and $684.76 for the PrecisionCHD™ test. This development is a crucial step toward expanding access to Medicare reimbursement, enhancing care for Medicare beneficiaries at risk for coronary heart disease. These rates are expected to be finalized later this year and will be effective for claims with dates of service on or after January 1, 2025. The approval is solely for Cardio Diagnostics Holdings Inc.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardio Diagnostics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722262254) on July 22, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。